Sort
82,697 grants matching “vaccine development”
Environmental/genetic Risk Factors and Pathogenesis of Autoimmune Disease
$1,931,828Frederick Miller · National Institute Of Environmental Health Sciences · ZIA · FY2011 · ES
Virus-Host Interactions: Induction and Evasion of Host Innate Immunity
$1,931,218Sonja Best · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
New Approaches to the Biology and Treatment of Myelodysplastic Syndromes (MDS)
$1,930,582Hagop Kantarjian · University Of Tx Md Anderson Can Ctr · P01 · FY2008 · CA
Live Vector Vaccines Against Agents of Bioterror
$1,930,417University Of Maryland Baltimore · U19 · FY2005 · AI
COALITION FOR HIV VACCINE DEVELOPMENT
$1,929,903University Of Maryland Baltimore · U01 · FY2002 · AI
Influenza vaccination using a microneedle patch
$1,928,072Mark R Prausnitz · Georgia Institute Of Technology · U01 · FY2014 · EB
Emerging Infections Program
$1,927,948Allen S. Craig · Tennessee State Department Of Health · U01 · FY2007 · CI
Natural History of HPV Infection in Men: The HIM Study
$1,927,539Anna R Giuliano · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2012 · CA
Molecular Determinants of Tissue-resident Memory T cell Fate in Acute and Chronic Infection
$1,926,207Ananda W Goldrath · University Of California, San Diego · P01 · FY2022 · AI
Clinical Trials of Biodefense Vaccines (Dengue)
$1,926,128Stephen Whitehead · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
First-In-Human Study of a Humanized Anti-Cocaine Monoclonal Antibody
$1,925,827Andrew B Norman · University Of Cincinnati · U01 · FY2020 · DA
Evaluation of the Immunogenicity and Efficacy of HIV-1 SOSIP Envelope Protein Vaccine Delivered with or without Recombinant Viral Vector Vaccines
$1,925,712Ronald S. Veazey · Tulane University Of Louisiana · N01 · FY2020 · AI
Development of a recombinant protein vaccine for Chlamydia trachomatis
$1,925,693Toni Darville · Univ Of North Carolina Chapel Hill · U01 · FY2025 · AI
PATHOGENESIS AND TREATMENT OF ACUTE HIV INFECTION
$1,925,423Bruce D Walker · Massachusetts General Hospital · U01 · FY2006 · AI
Cellular & Molecular Defects in Human B Cell Development
$1,925,282Charlotte Cunningham-Rundles · Icahn School Of Medicine At Mount Sinai · P01 · FY2012 · AI
Cellular & Molecular Defects in Human B Cell Development
$1,924,836Charlotte Cunningham-Rundles · Icahn School Of Medicine At Mount Sinai · P01 · FY2014 · AI
Cellular & Molecular Defects in Human B Cell Development
$1,924,821Charlotte Cunningham-Rundles · Icahn School Of Medicine At Mount Sinai · P01 · FY2015 · AI
Programming HIV Immunity for Broadly Neutralizing Antibodies by Vaccination
$1,924,641Nancy Logan Haigwood · Oregon Health & Science University · P01 · FY2011 · AI
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses
$1,924,593Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Integrase Defective Lentiviral Vector (IDLV)-ENV Immunogen Strategy for an HIV Vaccine
$1,924,538Mary E. Klotman · Duke University · P01 · FY2017 · AI
TempO-Seq Gene Expression Profiling of Intracellular Stained FACS Sorted Cells
$1,923,939Bruce E. Seligmann · Biospyder Technologies, Inc. · R44 · FY2017 · HG
Prophylactic Anthrax Toxin Vaccine
$1,923,739Vical, Inc. · R44 · FY2003 · AI
Sample Collection and General Screening Protocols
$1,923,376Lesia Dropulic · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Philadelphia IMPAACT Clinical Trials Unit
$1,922,500Steven Daniel Douglas · Children'S Hosp Of Philadelphia · UM1 · FY2012 · AI
Prevention of AIDS
$1,921,959Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA